{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:42:26Z","timestamp":1786452146498,"version":"build-2736575974"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032690","name":"Vyriad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>VV1 is designed to induce selective oncolysis of tumor cells and amplify cellular antitumor immune responses. This open-label, phase I, multicenter clinical trial assessed the safety and tolerability of VV1 monotherapy administered intratumorally or intravenously or administered intravenously in combination with avelumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with advanced solid tumors received intratumoral (n = 27) or intravenous VV1 monotherapy (n = 33) or intravenous VV1 plus avelumab (n = 16). Infusion durations (15\u2013180 minutes) and viral dose (1.7 \u00d7 1010 or 1 \u00d7 1011 TCID50) were also evaluated. Study objectives included VV1 safety and tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy, and immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Intratumoral and intravenous VV1 were well tolerated, and injection reactions were infrequent. The most common adverse events of any grade related to VV1 were cytokine release syndrome (58%), fatigue (33%), and decreased lymphocyte count (32%). Virus infection of tumors was confirmed by NIS imaging and increases in serum levels of virally encoded interferon-\u03b2 (IFN\u03b2). Histologic tumor analysis at 28 days after intratumoral VV1 administration indicated increases in tumor-infiltrating immune cells. Two durable partial responses were recorded: a patient with pheochromocytoma after one intravenous dose of VV1 and a patient with thymic cancer in the combination arm. Stable disease was observed in 17 of 49 patients (34.7%) who received intravenous VV1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This first-in-human study demonstrates that intratumoral or intravenous VV1 administration had an acceptable safety profile as monotherapy and intravenously in combination with avelumab. There is preliminary antitumor activity. Intratumoral VV1 plus cemiplimab is now showing promise in the neoadjuvant setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>VV1 is a tumor-selective oncolytic vesicular stomatitis virus engineered to express IFN\u03b2 and the thyroidal NIS reporter gene. In this phase I study, we have demonstrated that a single administration of VV1, as a monotherapy or with an immune checkpoint inhibitor is safe, infects tumor lesions resulting in intratumoral infiltration of immune cells, and exhibits early signs of antitumor activity in patients with advanced unresectable and metastatic solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0803","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:18:09Z","timestamp":1782155889000},"page":"1862-1874","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-4134","authenticated-orcid":false,"given":"Jaime R.","family":"Merchan","sequence":"first","affiliation":[{"name":"1University of Miami, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-945X","authenticated-orcid":false,"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zqws13","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Minnesota 2 , Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8595-3577","authenticated-orcid":false,"given":"Timothy P.","family":"Cripe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Nationwide Children\u2019s Hospital 3 , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1795-5877","authenticated-orcid":false,"given":"Matthew O.","family":"Old","sequence":"additional","affiliation":[{"name":"4Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0035-7654","authenticated-orcid":false,"given":"Jen","family":"Boughton","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-5679","authenticated-orcid":false,"given":"Rosa M.","family":"Diaz","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-7721","authenticated-orcid":false,"given":"Kah-Whye","family":"Peng","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."},{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 6 , Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8925-5163","authenticated-orcid":false,"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."},{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 6 , Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8381-0697","authenticated-orcid":false,"given":"Luke","family":"Russell","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-9187","authenticated-orcid":false,"given":"Nandakumar","family":"Packiriswamy","sequence":"additional","affiliation":[{"name":"5Vyriad, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7603-4368","authenticated-orcid":false,"given":"Erol","family":"Wiegert","sequence":"additional","affiliation":[{"name":"7Bexon Clinical Consulting LLC, Montclair, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1931-1153","authenticated-orcid":false,"given":"Alice S.","family":"Bexon","sequence":"additional","affiliation":[{"name":"7Bexon Clinical Consulting LLC, Montclair, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-0048","authenticated-orcid":false,"given":"Steven F.","family":"Powell","sequence":"additional","affiliation":[{"name":"8Sanford Health, Sioux Falls, South Dakota."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026081107570355100_bib1","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026081107570355100_bib2","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1002\/cti2.1226","article-title":"Therapeutic strategies to remodel immunologically cold tumors","volume":"9","author":"Wang","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"2026081107570355100_bib3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"2026081107570355100_bib4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026081107570355100_bib5","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"2026081107570355100_bib6","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026081107570355100_bib7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/OV.S66079","article-title":"Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy","volume":"4","author":"Simovic","year":"2015","journal-title":"Oncolytic Virother"},{"key":"2026081107570355100_bib8","volume-title":"Suspension for intralesional injection","author":"IMLYGIC\u00ae (talimogene laherparepvec)","year":"2023"},{"key":"2026081107570355100_bib9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"2026081107570355100_bib10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026081107570355100_bib11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026081107570355100_bib12","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: a systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026081107570355100_bib13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"2026081107570355100_bib14","doi-asserted-by":"publisher","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"key":"2026081107570355100_bib15","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1038\/sj.onc.1209042","article-title":"VSV-tumor selective replication and protein translation","volume":"24","author":"Barber","year":"2005","journal-title":"Oncogene"},{"key":"2026081107570355100_bib16","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"2026081107570355100_bib17","doi-asserted-by":"publisher","first-page":"898631","DOI":"10.3389\/fimmu.2022.898631","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026081107570355100_bib18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1517\/14712590903170653","article-title":"Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways","volume":"9","author":"Naik","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"2026081107570355100_bib19","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2012.70","article-title":"Curative one-shot systemic virotherapy in murine myeloma","volume":"26","author":"Naik","year":"2012","journal-title":"Leukemia"},{"key":"2026081107570355100_bib20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/1535-7163.MCT-17-0432","article-title":"Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer","volume":"17","author":"Naik","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026081107570355100_bib21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14712598.2016.1100162","article-title":"The use of the NIS reporter gene for optimizing oncolytic virotherapy","volume":"16","author":"Miller","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2026081107570355100_bib22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/humc.2013.165","article-title":"Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs","volume":"24","author":"LeBlanc","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2026081107570355100_bib23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2026081107570355100_bib24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1089\/humc.2017.015","article-title":"Oncolytic recombinant vesicular stomatitis virus (VSV) is nonpathogenic and nontransmissible in pigs, a natural host of VSV","volume":"28","author":"Velazquez-Salinas","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2026081107570355100_bib25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.ymthe.2017.05.006","article-title":"Oncolytic VSV primes differential responses to immuno-oncology therapy","volume":"25","author":"Durham","year":"2017","journal-title":"Mol Ther"},{"key":"2026081107570355100_bib26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"2026081107570355100_bib27","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1128\/jvi.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Obuchi","year":"2003","journal-title":"J Virol"},{"key":"2026081107570355100_bib28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026081107570355100_bib29","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1128\/JVI.02832-12","article-title":"PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice","volume":"87","author":"Tesfay","year":"2013","journal-title":"J Virol"},{"key":"2026081107570355100_bib30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2217\/fvl-2016-0129","article-title":"Designing and building oncolytic viruses","volume":"12","author":"Maroun","year":"2017","journal-title":"Future Virol"},{"key":"2026081107570355100_bib31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/mt.2015.219","article-title":"Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses","volume":"24","author":"Miller","year":"2016","journal-title":"Mol Ther"},{"key":"2026081107570355100_bib32","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2021006631","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv"},{"key":"2026081107570355100_bib33","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026081107570355100_bib34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"2026081107570355100_bib35","doi-asserted-by":"publisher","first-page":"105113","DOI":"10.1016\/j.esmoop.2025.105113","article-title":"LBA2 Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: results from the I-SPY 2.2 trial","volume":"10","author":"Yeung","year":"2025","journal-title":"ESMO Open"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0803\/3805151\/crc-25-0803.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1862\/3819189\/crc-25-0803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1862\/3819189\/crc-25-0803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:23:39Z","timestamp":1786451019000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1862\/787281\/Phase-I-Study-of-Oncolytic-Virus-VV1-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0803","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33205493","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165053","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205487","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165035","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165023","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165047","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205526","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205490","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165050","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205523","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205496","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165026","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33165038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33205505","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8636195","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}